← Latest news 
Aurobindo Pharma arm CuraTeQ clears Health Canada hurdle for biosimilar Bevqolva
Business
Published on 1 May 2026
Health Canada flags compliance for the bevacizumab biosimilar
Aurobindo Pharma said its subsidiary CuraTeQ Biologics has received a compliance notice from Health Canada for its cancer biosimilar Bevqolva, a bevacizumab-based treatment used across multiple cancers. The development signals Health Canada’s confirmation of safety and efficacy, paving the way for broader access to potential cost-effective options for patients in Canada.
- CuraTeQ Biologics received Health Canada compliance notice for Bevqolva
- Bevqolva is a bevacizumab biosimilar used for multiple cancers
- The nod reflects Health Canada confirmation of safety and efficacy
Read the full story at The Economic Times
This summarization was done by Beige for a story published on 
The Economic Times